Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Metabolic activity of gut bacteria can either promote or inhibit function of CAR T cells in cancer therapy (opens in a new tab)

medicalxpress.com · 2026-09-28

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

Metabolic activity of gut bacteria can either promote or inhibit function of CAR T cells in cancer therapy

medicalxpress.com · 2026-09-28

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 6Not checkedA new multicenter study reports that the metabolic products of gut bacteria, not only the composition of the gut microbiota, help determine the success of CAR T-cell therapy.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 6Not checkedThe study involved an observational cohort of 129 patients from three German university hospitals in Munich, Heidelberg, and Regensburg, and used microbiome and metabolome analyses to identify metabolites associated with response to or failure of CAR T-cell therapy.View evidenceHide evidence

As stated129 patients

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 6Not checkedThe researchers say certain microbial metabolites can enhance or inhibit CAR T-cell function, with valerate linked to better function and indole metabolites linked to worse outcomes in human and mouse models.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 6Not checkedLow pre-treatment valerate levels were associated with a higher risk of disease progression, while therapeutic administration improved CAR T-cell function in human and mouse models.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 6Not checkedElevated indole metabolites such as indole-3-carboxaldehyde and indole-3-acetic acid were linked to unfavorable outcomes and reduced CAR T-cell efficacy in human and mouse models.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 6 of 6Not checkedThe paper says a metabolite-based risk score predicted clinical response to CAR T-cell therapy, and the team is preparing a CARBiome clinical trial of microbiota transfer in multiple myeloma patients previously treated with antibiotics and scheduled for CAR T-cell therapy.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Opposing functions of gut immunomodulatory metabolites on CAR-T therapy

Cell · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed · 39 candidate papers

Candidate

Author response: Single-cell spatial mapping reveals reproducible cell type organization and spatially-dependent gene expression in gastruloids

2026 · Crossref

Source (opens in a new tab)
Candidate

We've Been down This Road before: Persistent Challenges in Dialysis Modality Survival Analyses

Clinical Journal of the American Society of Nephrology · 2026 · Crossref

Source (opens in a new tab)

And 33 more candidates considered.